Sep 2026
A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib.
BACKGROUND Pembrolizumab, a PD-1 immune checkpoint inhibitor, has shown promise in various cancers, but its role in ovarian cancer remains under investigation. While the current standard of care (SOC) is initially effective for epithelial ovarian cancer (EOC), approximately 70% of patients relapse within 3 years of com...
Carson C. Edwards, Kati A. Turner, Kaitlyn G. Dinkins et al.
· Gynecologic Oncology · 0 citations